Bioventus (BVS) Equity Average (2020 - 2026)

Bioventus has reported Equity Average for 7 years, with the latest figure at $208.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 12.47% year-over-year to $208.7 million; the trailing twelve-month figure through Mar 2026 stood at $208.7 million (up 12.47% YoY), and the FY2025 full-year result was $207.0 million, up 1.8% from the prior year.
• Equity Average for Q1 2026 stood at $208.7 million, up from $197.3 million in the prior quarter.
• The five-year high for Equity Average was $600.7 million in Q2 2022, with the low at $183.7 million in Q3 2025.
• Historically, Equity Average has averaged $289.9 million across 5 years, with a median of $219.3 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average soared 229.67% — and 2023, when it tumbled 60.05%.
• Bioventus' Equity Average stood at $431.6 million in 2022, then sank by 48.15% to $223.8 million in 2023, then declined by 16.79% to $186.2 million in 2024, then grew by 5.94% to $197.3 million in 2025, then gained by 5.78% to $208.7 million in 2026.
• The last three Equity Average figures came in at $208.7 million (Q1 2026), $197.3 million (Q4 2025), and $183.7 million (Q3 2025), per Business Quant data.